Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

34.46

+0.24 (0.70%)

as of Jun 25, 2026, 2:16:03 pm Market Open.

69 watching

Investor Insights

Jun 25, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Teva Pharmaceutical has shown significant improvement in its stock performance, with a notable increase of 264% since the beginning of 2023 under the leadership of its current CEO. Despite the challenges posed by the rising competition in the generic market, particularly for GLP drugs, the demand for these products remains robust. Innovations in drug formulations, such as pill-shaped GLPs, suggest a potential for future growth, yet experts highlight concerns about Teva's innovative capabilities. The company has been experiencing strong accumulation in recent months, breaking through key price resistance levels. Analysts project a price target of $34.50, though Teva currently does not offer dividends.

Consensus

Positive

Valuation

Undervalued

Similar

Pfeizer,PFE

STRONG BUY

Not sure why it has been beaten up so much but may have to do with a recent acquisition and concerns on how they are going to integrate it. 3 of the worst performing stocks this year are financials, pharmaceuticals and technology. Very, very cheap valuation. Raised its dividends 10 years in a row.

SELL

Really likes the generic drug business but he sold it because it is not a pure play generic. They also have the leading MS drug under patent. It will go off patent in the next year or so, so they also have a patent cliff. It is finally getting some real competition in the MS area. He decided to move on.

DON'T BUY

The largest generic drug producer but also have a branded division. There is concern that there will be increasing competition. As well, expect there will be increasing pressure for any industry that is being reimbursed by governments, especially the US. As the market improves, this stock should lift from here but longer-term, she wouldn't be a buyer.

COMMENT

Generic drugs plus one big branded drug that is going to face a lot of competition. Very attractive valuation. Not too excited about their acquisition of Cephalon. Not significantly adding to his holdings at this price. If you think it is going to recover, this is a great price.

STRONG BUY

Generic drug industry – governments should have preference for generic drugs. They will continue to grow. They had patent challenges from an MS drug they make. Should come to court in the fall. Market will eventually realize there is more value. Worth looking at. He was thinking of recommending it as a top pick today.

DON'T BUY

Recently sold his holdings. Liked the generic drug business. This one is not exclusively generic. Their biggest product that contributes the most to earnings is a multiple sclerosis drug and this will be coming off patent in the next couple of years. A lot of competition coming out on this drug.

DON'T BUY

Healthcare in the US had a pretty good run followed by a precipitous drop. There are probably better names.

COMMENT

Making all kinds of generic drugs and also do their own research/development and doing non-generic drugs as well. Not cheap enough for him to buy.

BUY

Generic drugs and its prospects are very strong. A lot of value under $50 a share. Trading at less than 10X earnings. Just made a big acquisition. Doing all the right things.

PAST TOP PICK

(A Top Pick Apr 29/10. Down 13.9%.) Still likes and is still buying. Suffered from headline risk on one of its drugs.

BUY

Lots of exciting news in the last 3 weeks. They have one blockbuster drug for MS. Another competitor came out with good results on the competing new drug. Cephalon is a small acquisition for them, but has 4 strong branded drugs. US Health care stocks have been beaten down too much and there are good entry points on a lot of names. Started buying TEVA about a month ago.

DON'T BUY

Had great growth over the last number of years. The big news was their outbidding Valeant (VRX-T) for Cephalon (CEPH-Q). Didn’t have to pay up much for this. This should keep growth going for them. He is not big on pharmaceuticals and sees no need to chase it at this price.

DON'T BUY

Buying Cephalon (CEPH-Q), which diversifies their revenue source from their branded drugs. Have a very successful branded drug for treating multiple cirrhosis but there is potential competition coming in the next couple of years. Trading at a very low multiple, below 10X. She prefers more diversified health care names.

COMMENT

Very big in the generic market. First class company. 1.5% yield. Would prefer Johnson & Johnson (JNJ-N).

BUY

Largest generic pharmaceutical company globally. Having a lot of trouble getting around $50. Great company and is not expensive. Earnings will come in around $5, trading at 10X earnings. Has a terrific outlook.

Showing 151 to 165 of 275 entries

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Virtus Investment Partners

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)